



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

Holly A. Wolfe  
Date of Signature

*Holly A. Wolfe*  
April 19, 2002

# 7  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Mount et al.

Group Art Unit: Not Assigned

**Serial No.: 09/835,976**

Examiner: Not Assigned

Filed: April 16, 2001

Docket No.: 1242/26/2

7/B

Confirmation No.: 3961

For: PURIFIED AND ISOLATED POTASSIUM-CHLORIDE COTRANSPORTER  
NUCLEIC ACIDS AND POLYPEPTIDES AND THERAPEUTIC AND  
SCREENING METHODS USING SAME

\*\*\*\*\*

STATEMENT THAT SEQUENCE LISTING AND  
COMPUTER READABLE COPY ARE THE SAME

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.821(f), applicants hereby state that the Sequence Listing information recorded in computer readable form is identical to the written Sequence Listing on paper.

Although that it is believed that no fee is due, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this correspondence to Deposit Account Number 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: 04/19/2002

By:

*Arlis A. Taylor, Jr.*  
Arlis A. Taylor, Jr.  
Registration No. 39,395

Suite 1400 University Tower  
3100 Tower Boulevard  
Durham, North Carolina 27707  
Telephone: (919) 493-8000  
Facsimile: (919) 419-0383

Customer No. Bar Code Label:



1242/26/2 AAT/JB/haw

25297

PATENT TRADEMARK OFFICE



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents, Washington, D.C. on

PATENT

Holly A. Wolfe  
Date of Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Mount et al.

Group Art Unit: Not Assigned

**Serial No.: 09/835,976**

Examiner: Not Assigned

Filed: April 16, 2001

Docket No.: 1242/26/2

Confirmation No.: 3961

For: PURIFIED AND ISOLATED POTASSIUM-CHLORIDE  
COTRANSPORTER NUCLEIC ACIDS AND POLYPEPTIDES AND  
THERAPEUTIC AND SCREENING METHODS USING SAME

\*\*\*\*\*

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR  
SEQUENCE DISCLOSURES

U.S. Patent and Trademark Office  
BOX SEQUENCE  
P.O. Box 2327  
Arlington, VA 22202

Sir:

This is responsive to the Notice to Comply dated March 12, 2002, having a 2-month term that expires on June 3, 2002. Favorable reconsideration is respectfully requested in view of the following Remarks and substitute Sequence Listing submitted under 37 C.F.R. § 1.821-1.825.

REMARKS

*Status Summary*

A substitute Sequence Listing is enclosed herewith as a computer-readable formatted (CRF) disk. The contents of the CRF of the Sequence Listing are identical to the contents of the paper copy of the Sequence Listing enclosed herewith. A statement to the effect is also enclosed. No new matter has been added. Thus, applicants believe this Response places the subject

application into compliance with the requirements of 37 C.F.R. § 1.821-1.825. Applicants respectfully request that the substitute CRF Sequence Listing and paper Sequence Listing be entered into the subject application.

DEPOSIT ACCOUNT

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any deficiencies of payment associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: 04/19/2002

By:



Arles A. Taylor, Jr.  
Registration No. 39,395

Suite 1400 University Tower  
3100 Tower Boulevard  
Durham, North Carolina 27707  
Telephone: (919) 493-8000  
Facsimile: (919) 419-0383



25297

PATENT TRADEMARK OFFICE


1242/26/2 AAT/JB/haw

Enclosures:

Copy of the Notice to Comply  
CRF Sequence Listing (diskette)  
Paper Copy of Sequence Listing  
Statement that CRF and paper Sequence Listing are identical  
Transmittal letter  
Postcard



## **RAW SEQUENCE LISTING ERROR REPORT**



0360

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/835,976A  
Source: OIPE  
Date Processed by STIC: 3/13/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: [patin3help@uspto.gov](mailto:patin3help@uspto.gov) or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER  
VERSION 3.1 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND  
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

# Raw Sequence Listing Error Summary

## ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER: 09/835,976

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1      Wrapped Nucleics      The number/text at the end of each line "wrapped" down to the next line.  
This may occur if your file was retrieved in a word processor after creating it.  
Please adjust your right margin to .3, as this will prevent "wrapping".
- 2      Wrapped Aminos      The amino acid number/text at the end of each line "wrapped" down to the next line.  
This may occur if your file was retrieved in a word processor after creating it.  
Please adjust your right margin to .3, as this will prevent "wrapping".
- 3      Incorrect Line Length      The rules require that a line not exceed 72 characters in length. This includes spaces.
- 4      Misaligned Amino Acid      The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs  
Numbering      between the numbering. It is recommended to delete any tabs and use spacing between the numbers.
- 5      Non-ASCII      This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.  
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
- 6      Variable Length      Sequence(s)      contain n's or Xaa's which represented more than one residue.  
As per the rules, each n or Xaa can only represent a single residue.  
Please present the maximum number of each residue having variable length and  
indicate in the (ix) feature section that some may be missing.
- 7      PatentIn ver. 2.0 "bug"      A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid  
sequence(s)                     . Normally, PatentIn would automatically generate this section from the  
previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section  
to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223>  
sections for Artificial or Unknown sequences.
- 8      Skipped Sequences      Sequence(s)      missing. If intentional, please use the following format for each skipped sequence:  
(OLD RULES)      (2) INFORMATION FOR SEQ ID NO:X:  
(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")  
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:  
This sequence is intentionally skipped  
  
Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
- 9      Skipped Sequences      Sequence(s)      missing. If intentional, please use the following format for each skipped sequence.  
(NEW RULES)      <210> sequence id number  
<400> sequence id number  
000
- 10    Use of n's or Xaa's      Use of n's and/or Xaa's have been detected in the Sequence Listing.  
(NEW RULES)      Use of <220> to <223> is MANDATORY if n's or Xaa's are present.  
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 11      Use of "Artificial"      Use of "Artificial" only as "<213> Organism" response is incomplete, per 1.823(b) of New Sequence Rules.  
(NEW RULES)      Valid response is Artificial Sequence.
- 12      Use of <220>Feature      Sequence(s)      are missing the <220>Feature and associated headings.  
(NEW RULES)      Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial Sequence" or "Unknown"  
Please explain source of genetic material in <220> to <223> section.  
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)
- 13      PatentIn ver. 2.0 "bug"      Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted  
file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).  
Instead, please use "File Manager" or any other means to copy file to floppy disk.



OIPE

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/835,976A

DATE: 03/13/2002  
TIME: 11:47:11

Input Set : A:\EP.txt  
Output Set: N:\CRF3\03132002\I835976A.raw

Does Not Comply  
Corrected Diskette Needed

3 <110> APPLICANT: Mount, David B.  
4 Delpire, Eric  
5 Gamba, Gerardo  
6 Alfred L. George, Jr.  
8 <120> TITLE OF INVENTION: PURIFIED AND ISOLATED POTASSIUM-CHLORIDE COTRANSPORTER  
NUCLEIC ACIDS AND  
9 POLYPEPTIDES AND  
10 THERAPEUTIC AND SCREENING METHODS USING SAME  
12 <130> FILE REFERENCE: Attorney Docket No. 1242-26-2  
C--> 14 <140> CURRENT APPLICATION NUMBER: US/09/835,976A  
C--> 15 <141> CURRENT FILING DATE: 2001-04-16  
17 <160> NUMBER OF SEQ ID NOS: 131  
19 <170> SOFTWARE: PatentIn Ver. 2.1

#### ERRORED SEQUENCES

4075 <210> SEQ ID NO: 14  
4076 <211> LENGTH: 1083  
4077 <212> TYPE: PRT  
4078 <213> ORGANISM: mouse  
4080 <220> FEATURE:  
4081 <221> NAME/KEY: misc\_feature  
4082 <222> LOCATION: (71)  
4083 <223> OTHER INFORMATION: Xaa=Leu or Ile  
4085 <220> FEATURE:  
4086 <221> NAME/KEY: misc\_feature  
4087 <222> LOCATION: (467)  
4088 <223> OTHER INFORMATION: Xaa=Leu or Ile  
4090 <220> FEATURE:  
4091 <221> NAME/KEY: misc\_feature  
4092 <222> LOCATION: (639)  
4093 <223> OTHER INFORMATION: Xaa=Leu or Ile  
4095 <400> SEQUENCE: 14  
4096 Met Pro Thr Asn Phe Thr Val Val Pro Val Glu Ala Arg Ala Asp Gly  
4097 1 5 10 15  
4099 Ala Gly Asp Glu Ala Ala Glu Arg Thr Glu Glu Pro Glu Ser Pro Glu  
4100 20 25 30  
4102 Ser Val Asp Gln Thr Ser Pro Thr Pro Gly Asp Gly Asn Pro Arg Glu  
4103 35 40 45  
4105 Asn Ser Pro Phe Ile Asn Asn Val Glu Val Glu Arg Glu Ser Tyr Phe  
4106 50 55 60  
4108 Glu Gly Lys Asn Met Ala Xaa Phe Glu Glu Glu Met Asp Ser Asn Pro  
4109 65 70 75 80

pg 1-4

what about Xaa at  
location 155? (p.2)

what about Xaa at  
location 586? (p.3)

what about  
Xaa at  
location 1023?  
(p.4)

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/835,976A

DATE: 03/13/2002

TIME: 11:47:12

Input Set : A:\EP.txt

Output Set: N:\CRF3\03132002\I835976A.raw

4111 Met Val Ser Ser Leu Leu Asn Lys Leu Ala Asn Tyr Thr Asn Leu Ser  
 4112 85 90 95  
 4114 Gln Gly Val Val Glu His Glu Glu Asp Glu Asp Ser Arg Arg Arg Glu  
 4115 100 105 110  
 4117 Val Lys Ala Pro Arg Met Gly Thr Phe Ile Gly Val Tyr Leu Pro Cys  
 4118 115 120 125  
 4120 Leu Gln Asn Ile Leu Gly Val Ile Leu Phe Leu Arg Leu Thr Trp Ile  
 4121 130 135 140  
 W--> 4123 Val Gly Ala Ala Gly Val Met Glu Ser Phe Xaa Ile Val Ala Met Cys  
 4124 145 150 155 160  
 4126 Cys Thr Cys Thr Met Leu Thr Ala Ile Ser Met Ser Ala Ile Ala Thr  
 4127 165 170 175  
 4129 Asn Gly Val Val Pro Ala Gly Gly Ser Tyr Tyr Met Ile Ser Arg Ser  
 4130 180 185 190  
 4132 Leu Gly Pro Glu Phe Gly Gly Ala Val Gly Leu Cys Phe Tyr Leu Gly  
 4133 195 200 205  
 4135 Thr Thr Phe Ala Gly Ala Met Tyr Ile Leu Gly Thr Ile Glu Ile Phe  
 4136 210 215 220  
 4138 Leu Thr Tyr Ile Ser Pro Ser Ala Ala Ile Phe Gln Ala Glu Thr Ala  
 4139 225 230 235 240  
 4141 Asp Gly Glu Ala Ala Ala Leu Leu Asn Asn Met Arg Val Tyr Gly Ser  
 4142 245 250 255  
 4144 Cys Ala Leu Ala Leu Met Ala Val Val Val Phe Val Gly Val Lys Tyr  
 4145 260 265 270  
 4147 Val Asn Lys Leu Ala Leu Val Phe Leu Ala Cys Val Val Leu Ser Ile  
 4148 275 280 285  
 4150 Leu Ala Ile Tyr Ala Gly Val Ile Lys Thr Ala Phe Ala Pro Pro Asp  
 4151 290 295 300  
 4153 Ile Pro Val Cys Leu Leu Gly Asn Arg Thr Leu Ala Asn Arg Asn Phe  
 4154 305 310 315 320  
 4156 Asp Thr Cys Ala Lys Met Gln Val Val Ser Asn Gly Thr Val Thr Thr  
 4157 325 330 335  
 4159 Ala Leu Trp Arg Leu Phe Cys Asn Gly Ser Ser Leu Gly Ala Thr Cys  
 4160 340 345 350  
 4162 Asp Glu Tyr Phe Ala Gln Asn Asn Val Thr Glu Ile Gln Gly Ile Pro  
 4163 355 360 365  
 4165 Gly Val Ala Ser Gly Val Phe Leu Asp Asn Leu Trp Ser Thr Tyr Ser  
 4166 370 375 380  
 4168 Asp Lys Gly Ala Phe Val Glu Lys Lys Gly Val Ser Ser Val Pro Val  
 4169 385 390 395 400  
 4171 Ser Glu Glu Ser Arg Pro Gly Gly Leu Pro Tyr Val Leu Thr Asp Ile  
 4172 405 410 415  
 4174 Met Thr Tyr Phe Thr Met Leu Val Gly Ile Tyr Phe Pro Ser Val Thr  
 4175 420 425 430  
 4177 Gly Ile Met Ala Gly Ser Asn Arg Ser Gly Asp Leu Lys Asp Ala Gln  
 4178 435 440 445  
 4180 Lys Ser Ile Pro Thr Gly Thr Ile Leu Ala Ile Val Thr Thr Ser Phe  
 4181 450 455 460  
 W 4183 Ile Tyr Xaa Ser Cys Ile Val Leu Phe Gly Ala Cys Ile Glu Gly Val

## RAW SEQUENCE LISTING

DATE: 03/13/2002

PATENT APPLICATION: US/09/835,976A

TIME: 11:47:12

Input Set : A:\EP.txt

Output Set: N:\CRF3\03132002\I835976A.raw

4184 465 470 475 480  
 4186 Val Leu Arg Asp Lys Phe Gly Glu Ala Leu Gln Gly Asn Leu Val Ile  
 4187 485 490 495  
 4189 Gly Met Leu Ala Trp Pro Ser Pro Trp Val Ile Val Ile Gly Ser Phe  
 4190 500 505 510  
 4192 Phe Ser Thr Cys Gly Ala Gly Leu Gln Ser Leu Thr Gly Ala Pro Arg  
 4193 515 520 525  
 4195 Leu Leu Gln Ala Ile Ala Arg Asp Gly Ile Ile Pro Phe Leu Gln Val  
 4196 530 535 540  
 4198 Phe Gly His Gly Lys Ala Asn Gly Glu Pro Thr Trp Ala Leu Leu Leu  
 4199 545 550 555 560  
 4201 Thr Ala Leu Ile Cys Glu Thr Gly Ile Leu Ile Ala Ser Leu Asp Ser  
 4202 565 570 575  
 W--> 4204 Val Ala Pro Ile Leu Ser Met Phe Phe Xaa Met Cys Tyr Met Phe Val  
 4205 580 585 590  
 4207 Asn Leu Ala Cys Ala Val Gln Thr Leu Leu Arg Thr Pro Asn Trp Arg  
 4208 595 600 605  
 4210 Pro Arg Phe Lys Phe Tyr His Trp Thr Leu Ser Phe Leu Gly Met Ser  
 4211 610 615 620  
 W--> 4213 Leu Cys Leu Ala Leu Met Phe Ile Cys Ser Trp Tyr Tyr Ala Xaa Phe  
 4214 625 630 635 640  
 4216 Ala Met Leu Ile Ala Gly Cys Ile Tyr Lys Tyr Ile Glu Tyr Arg Gly  
 4217 645 650 655  
 4219 Ala Glu Lys Glu Trp Gly Asp Gly Ile Arg Gly Leu Ser Leu Asn Ala  
 4220 660 665 670  
 4222 Ala Arg Tyr Ala Leu Leu Arg Val Glu His Gly Pro Pro His Thr Lys  
 4223 675 680 685  
 4225 Asn Trp Arg Pro Gln Val Leu Val Met Leu Asn Leu Asp Ser Glu Gln  
 4226 690 695 700  
 4228 Cys Val Lys His Pro Arg Leu Leu Ser Phe Thr Ser Gln Leu Lys Ala  
 4229 705 710 715 720  
 4231 Gly Lys Gly Leu Thr Ile Val Gly Ser Val Leu Glu Gly Thr Tyr Leu  
 4232 725 730 735  
 4234 Asp Lys His Val Glu Ala Gln Arg Ala Glu Glu Asn Ile Arg Ser Leu  
 4235 740 745 750  
 4237 Met Ser Ala Glu Lys Thr Lys Gly Phe Cys Gln Leu Val Val Ser Ser  
 4238 755 760 765  
 4240 Asn Leu Arg Asp Gly Ala Ser His Leu Ile Gln Ser Ala Gly Leu Gly  
 4241 770 775 780  
 4243 Gly Met Lys His Asn Thr Val Leu Met Ala Trp Pro Glu Ala Trp Lys  
 4244 785 790 795 800  
 4246 Glu Ala Asp Asn Pro Phe Ser Trp Lys Asn Phe Val Asp Thr Val Arg  
 4247 805 810 815  
 4249 Asp Thr Thr Ala Ala His Gln Ala Leu Leu Val Ala Lys Asn Ile Asp  
 4250 820 825 830  
 4252 Leu Phe Pro Gln Asn Gln Glu Arg Phe Ser Asp Gly Asn Ile Asp Val  
 4253 835 840 845  
 4255 Trp Trp Ile Val His Asp Gly Gly Met Leu Met Leu Leu Pro Phe Leu  
 4256 850 855 860

Use of n and/or Xaa has been detected in the Sequence Listing.  
 Review the Sequence Listing to insure a corresponding  
 explanation is presented in the <220> to <223> fields of  
 each sequence using n or Xaa.



## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/835,976A

DATE: 03/13/2002

TIME: 11:47:12

Input Set : A:\EP.txt

Output Set: N:\CRF3\03132002\I835976A.raw

```

4258 Leu Arg Gln His Lys Val Trp Arg Lys Cys Arg Met Arg Ile Phe Thr
4259 865                               870                               875                               880
4261 Val Ala Gln Val Asp Asp Asn Ser Ile Gln Met Lys Lys Asp Leu Gln
4262                               885                               890                               895
4264 Met Phe Leu Tyr His Leu Arg Ile Ser Ala Glu Val Glu Val Val Glu
4265                               900                               905                               910
4267 Met Val Glu Asn Asp Ile Ser Ala Phe Thr Tyr Glu Lys Thr Leu Met
4268                               915                               920                               925
4270 Met Glu Gln Arg Ser Gln Met Leu Lys Gln Met Gln Leu Ser Lys Asn
4271                               930                               935                               940
4273 Glu Arg Glu Arg Glu Ala Gln Leu Ile His Asp Arg Asn Thr Ala Ser
4274 945                               950                               955                               960
4276 His Thr Thr Ala Thr Ala Arg Thr Gln Ala Pro Pro Thr Pro Asp Lys
4277                               965                               970                               975
4279 Val Gln Met Thr Trp Thr Lys Glu Lys Leu Ile Ala Glu Lys His Arg
4280                               980                               985                               990
4282 Asn Lys Asp Thr Gly Pro Ser Gly Phe Lys Asp Leu Phe Ser Leu Lys
4283                               995                               1000                               1005
W--> 4285 Pro Asp Gln Ser Asn Val Arg Arg Met His Thr Ala Val Lys Xaa Asn
4286                               1010                               1015                               1020
4288 Gly Val Val Leu Asn Lys Ser Gln Asp Ala Gln Leu Val Leu Leu Asn
E--> 4289 1025                               1030                               1035                               1040
4291 Met Pro Gly Pro Pro Lys Ser Arg Gln Gly Asp Glu Asn Tyr Met Glu
4292                               1045                               1050                               1055
4294 Phe Leu Glu Val Leu Thr Glu Gly Leu Asn Arg Val Leu Leu Val Arg
E--> 4295                               1060                               1065                               1070
4297 Gly Gly Gly Arg Glu Val Ile Thr Ile Tyr Ser
4298                               1075                               1080

```

see below

1) begin the amino acid number directly below the first letter of the amino acid. Do not have any part of the number under the letters of the next amino acid.

e.g. Lys | S | Ser  
 1030 | e |

2) When numbering the last amino acid on a line, please end the number directly below the last letter of the amino acid

Leu | S | Asn  
 1040 | e |

## VERIFICATION SUMMARY

PATENT APPLICATION: US/09/835,976A

DATE: 03/13/2002

TIME: 11:47:13

Input Set : A:\EP.txt

Output Set: N:\CRF3\03132002\I835976A.raw

L:14 M:270 C: Current Application Number differs, Replaced Application Number  
L:15 M:271 C: Current Filing Date differs, Replaced Current Filing Date  
L:59 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1  
L:60 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1  
L:67 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1  
L:68 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1  
L:303 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1  
L:304 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1  
L:417 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2  
L:423 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2  
L:600 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2  
L:650 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3  
L:651 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3  
L:762 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3  
L:763 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3  
L:910 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3  
L:911 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3  
L:981 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4  
L:1062 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4  
L:1176 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4  
L:1239 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5  
L:1240 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5  
L:1371 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5  
L:1372 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5  
L:1491 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5  
L:1492 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5  
L:1630 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6  
L:1729 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6  
L:1819 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6  
L:1858 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7  
L:1859 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7  
L:1926 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7  
L:1927 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7  
L:2062 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7  
L:2063 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7  
L:2510 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9  
L:2511 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9  
L:2630 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9  
L:2631 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9  
L:2738 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9  
L:2739 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9  
L:2895 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10  
L:2982 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10  
L:3063 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10  
L:3143 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11  
L:3144 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11  
L:3203 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11  
L:3204 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11

## VERIFICATION SUMMARY

PATENT APPLICATION: US/09/835,976A

DATE: 03/13/2002

TIME: 11:47:13

Input Set : A:\EP.txt

Output Set: N:\CRF3\03132002\I835976A.raw

L:3343 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11  
L:3344 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11  
L:3524 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12  
L:3569 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12  
L:4289 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:14  
M:332 Repeated in SeqNo=14  
L:6706 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:111  
L:6834 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:112  
L:7185 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:131